Organogenesis Holdings (ORGO) Income from Continuing Operations (2016 - 2026)

Organogenesis Holdings has reported Income from Continuing Operations for 11 years, with the latest figure at -$96.3 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 924.99% year-over-year to -$96.3 million in Q2 2026; TTM through Jun 2026 was -$84.2 million, a 344.09% decrease from a year earlier, with the FY2025 full-year figure at $37.0 million, up 475.65% from the prior year.
• Income from Continuing Operations was -$96.3 million for Q2 2026 at Organogenesis Holdings, down from -$53.2 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $43.7 million in Q4 2025, with the low at -$96.3 million in Q2 2026.
• Average Income from Continuing Operations over 5 years is -$5.7 million, with a median of -$740500.0 recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 1534.67% in 2025, then plunged 924.99% in 2026.
• Over 5 years, Income from Continuing Operations stood at $7.5 million in 2022, then slumped by 107.59% to -$568000.0 in 2023, then slumped by 436.27% to -$3.0 million in 2024, then surged by 1534.67% to $43.7 million in 2025, then plunged by 320.29% to -$96.3 million in 2026.
• The last three Income from Continuing Operations figures came in at -$96.3 million (Q2 2026), -$53.2 million (Q1 2026), and $43.7 million (Q4 2025), per Business Quant data.